News
Redhill Biopharma Terminates Agreement With Movantik Acquisition, Valinor Pharma, And Hcr Redhill, And Received ~$9.9M In Cash And Gained Full Control Over An Additional $0.74M Currently Held In Restricted Account
22 Jul 24
Biotech, News, Health Care, General
RedHill Biopharma Terminates License Agreement For Aemcolo, A Treatment For Traveler's Diarrhea, Will Be Officially Terminated On October 8, 2024
9 Jul 24
News, Contracts
12 Health Care Stocks Moving In Tuesday's After-Market Session
18 Jun 24
Movers
RedHill Biopharma Has Received A Notice Of Allowance For Its U.S. Patent Application 17/900,235 titled "BIOMARKERS OF CORONAVIRUS PNEUMONIA (FOR TREATING CORONAVIRUS INFECTION OR PREVENTING DISEASES CAUSED BY CORONAVIRUS INFECTION)"
18 Jun 24
Biotech, News, General
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
6 May 24
Government, News, Regulations
Press releases
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
22 Jul 24
Press Releases
RedHill Biopharma Terminates License Agreement for Aemcolo®
9 Jul 24
Press Releases
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
3 Jun 24
Press Releases
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
6 May 24
Press Releases